Sorafenib exhibits a dual mechanism of action by inhibiting VEGFRs and PDGFR signaling and thus inhibiting the RAF/MEK/extracellular signal-regulated kinase (ERK) pathway to reduce tumor angiogenesis and to induce tumor cell apoptosis (Ramakrishnan et al., 2010). This evidence concerns the gene PDGFRB and neoplasm.